结合隐匿性脑血管损伤与临床特征优化长期抗栓治疗的预测模型
基于日本52家医院的前瞻性多中心观察性研究(BAT2),纳入5250例口服抗血小板或抗凝药患者,利用基线多模态脑MRI评估脑小血管病等指标,开发BAT2评分分别预测大出血、颅内出血和缺血性卒中。模型区分度中等,有助于个体化权衡抗栓治疗的获益与风险。
要点
- BAT2评分分别预测大出血、颅内出血和缺血性卒中,区分度中等。
- 脑微出血、腔隙灶等隐匿性脑血管损伤纳入出血风险预测。
- 该评分有助于个体化优化抗栓治疗的净临床获益。
核心结论
- BAT2评分可能有助于优化抗栓治疗的风险与获益平衡。
研究设计与样本
- 前瞻性多中心观察性研究(BAT2),2016至2019年日本52家医院纳入口服抗血小板或抗凝药患者。
- 共5378例入组,5250例分析,平均年龄71±11岁,女性33%。
主要发现
- 中位随访2.0年,93例发生大出血(含55例颅内出血),197例发生缺血性卒中。
- 出血预测因子包括年龄、低体重、肾损害、高血压、脑微出血、腔隙灶及抗栓治疗类型。
- 颅内出血预测因子进一步包括深部白质高信号但不包括肾损害。
- 缺血性卒中预测因子包括年龄、肾损害、糖尿病、房颤、腔隙灶、脑微出血、非腔隙性梗死及颅内动脉病变。
- 乐观校正后C指数:出血0.69(95%CI 0.64-0.74),颅内出血0.75(95%CI 0.67-0.80),缺血性卒中0.64(95%CI 0.60-0.68)。
关键数值与推荐
- 校准斜率:出血0.82(95%CI 0.62-1.06),颅内出血0.80(95%CI 0.56-1.02),缺血性卒中0.92(95%CI 0.73-1.18)。
临床怎么用
- 对于长期口服抗栓治疗患者,可结合BAT2评分及脑MRI隐匿性脑血管损伤评估个体化出血与缺血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Defining the risk of developing major bleeding, especially intracranial hemorrhage (ICH), or ischemic stroke (IS) in patients receiving antithrombotic therapy is crucial. Existing risk prediction tools would inadequately assess the net clinical benefit of antithrombotic therapy. We aimed to develop novel risk scores incorporating covert vascular brain injury to personalize the risk assessment of major bleeding, ICH, and IS in patients receiving antithrombotic therapy. METHODS: The prospective, multicenter, observational study (BAT2 [Bleeding With Antithrombotic Therapy Study-2]) enrolled patients receiving oral antiplatelets or anticoagulants from 52 hospitals across Japan between 2016 and 2019. Multimodal brain magnetic resonance imaging was performed at baseline under prespecified conditions to determine cerebral small vessel disease (white matter hyperintensity, cerebral microbleed, lacune, enlarged perivascular space, and cortical superficial siderosis), nonlacunar infarct, and intracranial artery disease with central reading. Risk scores, collectively termed the BAT2 scores, were developed separately to evaluate the comparative risks of (1) major bleeding, (2) ICH, and (3) IS based on covariates from Cox proportional hazards models and clinical relevance. Model performance was assessed with the Harrell C-index and calibration slope adjusted for optimism via bootstrapping. RESULTS: Of 5378 patients enrolled, 5250 were analyzed (mean age, 71±11 years, 33% women); 93 experienced major bleeding, including 55 had ICH, and 197 had IS during a median follow-up of 2.0 years. Predictors for bleeding included age, underweight, renal impairment, hypertension, cerebral microbleed, lacune, and antithrombotic treatment type. Predictors for ICH further included deep white matter hyperintensity but not renal impairment. For IS, predictors included age, renal impairment, diabetes, atrial fibrillation, lacune, cerebral microbleed, nonlacunar infarct, and intracranial artery disease. Prediction performance showed optimism-adjusted C-index and calibration slope of 0.69 (95% CI, 0.64-0.74) and 0.82 (95% CI, 0.62-1.06) for bleeding, 0.75 (95% CI, 0.67-0.80) and 0.80 (95% CI, 0.56-1.02) for ICH, and 0.64 (95% CI, 0.60-0.68) and 0.92 (95% CI, 0.73-1.18) for IS. CONCLUSIONS: The BAT2 scores may help optimize the balance between risks and benefits of antithrombotic therapy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02889653. URL: https://www.umin.ac.jp/ctr; Unique identifier: UMIN000023669.
引用
- Miwa K, Tanaka K, Koga M, et al. Prediction Model to Optimize Long-Term Antithrombotic Therapy Using Covert Vascular Brain Injury and Clinical Features. Stroke. 2025. PMID: 40534562. doi:10.1161/STROKEAHA.125.050859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。